title: Associations of NR5A2 gene polymorphisms with the clinicopathological characteristics and survival of gastric cancer.
abstract: The orphan nuclear receptor (NR5A2), which belongs to the NR5A subfamily of nuclear receptors, is expressed in developing and adult tissues of endodermal origin, and can contribute to the development of several cancers through regulating cell proliferation. NR5A2 (rs3790843 and rs3790844) single nucleotide polymorphisms (SNPs) genotyping were examined in DNA samples, extracted from paraffin-embedded cancer tissue. Clinicopathologic and follow-up data were collected from 944 patients with gastric cancer (GC). Associations of the 2 SNPs with the progression and prognosis in gastric cancer patients were analyzed using the SPSS version 18.0. We found that NR5A2 rs3790843 polymorphism was significantly associated with the risk of GC which had regional lymph node metastasis (p = 0.044) or distant metastasis (p = 0.020). Our results also indicated that rs3790844 polymorphism was associated with the increased overall survival (OS) of GC patients in the dominant model (GG vs. GA/AA, HR (hazard ratio) = 0.823, 95% CI (confidence interval) = 0.679-0.997), suggesting a potential protective role of the variant A allele. Additionally, in the stratified analysis, both NR5A2 rs3790843 and rs3790844 polymorphism were associated with significantly lower risk of death in the groups of female, tumor size >5 cm in a dominant model. Our results represent the first demonstration that the NR5A2 rs3790844 polymorphism is associated with increased OS of GC patients in the dominant model, and similar results were found among the female group and tumor size >5 cm group for NR5A2 rs3790843 polymorphism. Further validation in other larger studies with different ethnic populations and functional evaluations are needed.
authors.affiliation: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. zhangxunlei1@sina.com.
authors.forename: Xunlei
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. gu_dongying@sina.com.
authors.forename: Dongying
authors.initials: D
authors.lastname: Gu
authors.affiliation: Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing 211166, China. dumulong@163.com.
authors.forename: Mulong
authors.initials: M
authors.lastname: Du
authors.affiliation: Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing 211166, China. meilin_w@163.com.
authors.forename: Meilin
authors.initials: M
authors.lastname: Wang
authors.affiliation: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. chunxiang198722@163.com.
authors.forename: Chunxiang
authors.initials: C
authors.lastname: Cao
authors.affiliation: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. shenlilimao2012@163.com.
authors.forename: Lili
authors.initials: L
authors.lastname: Shen
authors.affiliation: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. jhcxy1225@126.com.
authors.forename: Meng
authors.initials: M
authors.lastname: Kuang
authors.affiliation: Department of Surgery, Yixing People's Hospital, Yixing 214200, China. shelly37319@126.com.
authors.forename: Yongfei
authors.initials: Y
authors.lastname: Tan
authors.affiliation: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. huoxinying2008@126.com.
authors.forename: Xinying
authors.initials: X
authors.lastname: Huo
authors.affiliation: Department of General Surgery, Yixing Tumor Hospital, Yixing 214200, China. gongweida2010@gmail.com.
authors.forename: Weida
authors.initials: W
authors.lastname: Gong
authors.affiliation: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. michelle.xuzhi@gmail.com.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Xu
authors.affiliation: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. jinfeichen@sohu.com.
authors.forename: Jinfei
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing 211166, China. drzdzhang@sina.com.
authors.forename: Zhengdong
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. tangcuiju@tom.com.
authors.forename: Cuiju
authors.initials: C
authors.lastname: Tang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D005260:Female; D005500:Follow-Up Studies; D056726:Genetic Association Studies; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D063868:Patient Outcome Assessment; D011110:Polymorphism, Genetic; D011379:Prognosis; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics*; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D047368:Tumor Burden
chemical_list: C082631:NR5A2 protein, human; D018160:Receptors, Cytoplasmic and Nuclear